Editas Medicine, Inc. 8K

Editas Medicine reported Q2 2026 results, advanced its EDIT-401 program toward a Phase 1/2 trial with an imminent CTN filing in Australia, strengthened its balance sheet via a $125 million equity offering extending runway into H2 2028, and added Patrick T. Ellinor to its Board.

On August 5, 2026, Editas Medicine, Inc. reported its second quarter 2026 financial results and provided business updates, highlighting progress on its lead EDIT-401 in vivo gene-editing program for heterozygous familial hypercholesterolemia, including strong preclinical efficacy and safety data in non-human primates, plans to submit a Clinical Trial Notification in Australia this month and initiate a Phase 1/2 trial with initial data expected in the first quarter of 2027, and a strengthened capital position following a $125 million equity offering that, together with existing cash, extends its runway into the second half of 2028, alongside the appointment of cardiovascular expert Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors and a significantly narrowed quarterly net loss versus the prior year.

Filing Facts

CIK

1650664

Ticker

-

Form

8K

Source Type

sec

Accession

0001650664-26-000082

Alert Tier

6